J.Jpn. Surg. Soc.
ISSN 1880-1129

[Abstract] [Full Text PDF] （in Japanese / 3066KB） [Members Only And Two Factor Auth.]

J.Jpn. Surg. Soc.. 103(2): 237-243, 2002

Feature topic

DEVELOPMENT OF ANTIANGIOGENIC CHEMOTHERAPY REGIMENS

1) Department of Thoracic surgery, Thoracic Cancer Center, Sendai Kosei hospital, Sendai, Japan
2) Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan

Hiroto Takahashi1), Takashi Kondo2)

Research in tumor angiogenesis is making tapid progress. It was recently confirmed that tumors utilize both vasculogenesis and existing blood vessels for angiogenesis, and angiogenesis has become a molecular target of new cancer therapies. Numerous inhibitors of angiogenesis have been developed and clinical trials conducted. However. problems such as side effects and the appropriate design of clinical trials have been noted and the development of some inhibitors has stalled. Therefore more time and study will be required before clinical application of angiogensis inhibitors is feasible. Trials combining existing chemotherapeutic regimens with angiogenesis inhibitors is feasible. Trials combining existing chemotherapeutic regimens with angiogenesis inhibitors, i.e., antiangiogenic chemotherapy, are underway in which low-dose anticancer and antiangiogenic agents are administered daily over the long term, and the results are awaited.

<< To previous pageTo next page >>

To read the PDF file you will need Adobe Reader installed on your computer.